Track Ipca Laboratories Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 9.38 %
Low
1,605.3
High
1,775.0
1 Month returns: 14.17 %
Low
1,530.0
High
1,775.0
1 Year returns: 25.16 %
Low
1,251.6
High
1,775.0
3 Year CAGR: 33.22 %
Low
743.0
High
1,775.0
5 Year CAGR: 11.97 %
Low
669.8
High
1,775.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Ipca Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Ipca Laboratories Ltd. Shareholding Pattern
Quarterly breakdown of Ipca Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Ipca Laboratories Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Ipca Laboratories Ltd.?
The current share price of Ipca Laboratories Ltd. is ₹ 1,771.90 as of 3 Jul 2026.
What is the market capitalisation of Ipca Laboratories Ltd.?
The market capitalisation of Ipca Laboratories Ltd. stands at ₹ 43,586.30 Cr.
What is the PE ratio of Ipca Laboratories Ltd.?
The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd. is 38.20 as of the latest trailing twelve months data.
What is the ROE and ROCE of Ipca Laboratories Ltd.?
Ipca Laboratories Ltd. has a Return on Equity (ROE) of 15.20% and a Return on Capital Employed (ROCE) of 15.54% as per the latest financial reports.
What is the 52-week high and low of Ipca Laboratories Ltd.?
The 52-week high of Ipca Laboratories Ltd. is - and the 52-week low is -.
What is the dividend yield of Ipca Laboratories Ltd.?
The dividend yield of Ipca Laboratories Ltd. is 0.12% based on the current market price.
What is the FII and DII holding in Ipca Laboratories Ltd.?
Foreign Institutional Investors (FII) hold 10.63%, Domestic Institutional Investors (DII) hold 36.58% and retail/public investors hold 6.87% of Ipca Laboratories Ltd. shares.
What sector does Ipca Laboratories Ltd. belong to?
Ipca Laboratories Ltd. operates in the Healthcare sector. 85.71% of analysts have a Buy or Strong Buy rating on Ipca Laboratories Ltd. with a consensus target price of ₹ 1,730.00, implying 0.7% upside from current levels.
What is the beta of Ipca Laboratories Ltd.?
The beta of Ipca Laboratories Ltd. is -0.02, indicating its price volatility relative to the broader market. Over the past 1 year, Ipca Laboratories Ltd. has delivered an absolute return of 28.75%.
What is the RSI of Ipca Laboratories Ltd.?
The 14-day Relative Strength Index (RSI) of Ipca Laboratories Ltd. is 69.67, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Company Profile
Overview of Ipca Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquin...
Key personnel
Mr. Pabitra Kumar Bhattacharya
President - Operations (API)
Mr. Sunil Ghai
President - Marketing
Dr. Sanjay U. Kapadia
President - Corporate Quality Assurance
Dr. Ashok Kumar
President - Research and Development (Chemicals)
Mr. Shailesh Laul
President - Operations (Formulations)
Mr. Hitesh Kumar Maheshwari
President - Research and Development (Formulations)
Fundamental analysis overview of Ipca Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 88.4 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
88.4 / 100
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 1.68% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
High and improving ROE
The company reported strong ROE of 15.2% for 12-month ended 31 Mar 2026 and ROE improved by 409 bps from 1 year ago
What is ROE (FY)?
High and stable operating margin
The company reported strong operating margin of 16.18% for 12-month ended 31 Mar 2026 and operating margin improved marginally by 132 bps from 1 year ago
What is Operating profit margin?
Strong EPS growth and above median growth of industry
The company delivered strong EPS growth of 54.7% for 12-month ended 31 Mar 2026 and the growth was 46.58 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.1 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.1 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 9 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 38.2 indicates that the stock is expensive on a standalone basis and is at a 26.24% premium to industry median P/E
What is P/E Ratio?
Median: 30.26
Value 38.2
-215.443183
Low revenue growth and lower than median growth of industry
The company delivered moderate revenue growth of 8.42% for 12-month ended 31 Mar 2026 and the growth was 2.82 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 11.24
Value 8.42
-82.35114662
Low dividend yield
The company has a low dividend yield of 0.12%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 66.1 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
66.1 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
MANISH KUMAR JAIN
Designated Person
February-2026
Market Sale (Disposal)
18th Feb 2026
0.01 %
₹ 1,482.22
3.00 k
₹ 44.47 lac
Pawan Kothari
Designated Person
August-2025
Market Sale (Disposal)
25th Aug 2025
0.00 %
₹ 1,413.02
2.22 k
₹ 31.37 lac
Mrs. Usha M. Chandurkar
Promoter Group
December-2024
Market Sale (Disposal)
19th Dec 2024
3.27 %
₹ 1,499.25
40.00 lac
₹ 599.70 cr
Paschim Chemicals Pvt. Ltd.
Promoter Group
March-2024
Market Purchase (Acquisition)
12th Mar 2024
4.00 %
₹ 1,200.97
35.00 k
₹ 4.20 cr
Mr. Ajit Kumar Jain
Director
November-2023
Market Sale (Disposal)
20th Nov 2023
0.02 %
₹ 1,081.85
20.00 k
₹ 2.16 cr
Mr. E. J. Babu Former Designated Employee
Other
September-2022
Market Sale (Disposal)
19th Sep 2022
0.01 %
₹ 874.39
2.00 k
₹ 17.49 lac
Mr. A. K. Jain
Director
March-2022
Market Sale (Disposal)
21st Mar 2022
0.03 %
₹ 1,026.82
20.00 k
₹ 2.05 cr
Kavita Sehwani
Designated Person
August-2021
Market Sale (Disposal)
26th Aug 2021
0.02 %
₹ 2,441.16
450.00
₹ 10.99 lac
Pabitra Kumar Bhattacharyya
Designated Person
August-2021
Market Sale (Disposal)
23rd Aug 2021
0.00 %
₹ 2,510.00
4.00 k
₹ 1.00 cr
Ajit Kumar Jain
Director
August-2021
Market Sale (Disposal)
19th Aug 2021
0.04 %
₹ 2,421.90
10.00 k
₹ 2.42 cr
Corporate Actions
History of Ipca Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.